HS
NAMS icon

HighVista Strategies’s NewAmsterdam Pharma NAMS Stock Holding History

HighVista Strategies’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Buy
20,905
+838
+4% +$27.6K 0.16% 134
2026
Q1 		$642K Sell
20,067
-15,519
-44% -$506K 0.18% 140
2025
Q4 		$1.25M Buy
35,586
+3,755
+12% +$137K 0.32% 85
2025
Q3 		$905K Buy
31,831
+12,557
+65% +$301K 0.22% 127
2025
Q2 		$349K Buy
+19,274
New +$352K 0.13% 137

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

HighVista Strategies's NAMS Position: Q2 2026 in Review

HighVista Strategies increased its NewAmsterdam Pharma (NAMS) stake by 4.2% in Q2 2026, buying an estimated $27.6K and bringing the position to 20,905 shares worth $708K. The position accounts for 0.16% of the portfolio, ranked #134.

HighVista Strategies first reported a position in NAMS in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.25M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • HighVista Strategies held 20,905 shares of NewAmsterdam Pharma worth $708K as of Q2 2026.
  • HighVista Strategies bought 838 NewAmsterdam Pharma shares in Q2 2026, an estimated $27.6K.
  • NewAmsterdam Pharma made up 0.16% of HighVista Strategies's portfolio in Q2 2026, its #134 holding.
  • HighVista Strategies first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 5 quarters since.
  • HighVista Strategies's NewAmsterdam Pharma position peaked at $1.25M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.